secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0001516551-24-000052
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience reports pro forma equity >$5M after $90M private placement
--------------------------------------------------------------------------

- Closed private placement of 15.7M shares and 10.0M pre-funded warrants for $90M gross ($83.5M net).
- Sold real estate held by subsidiary Avalite Sciences, recording $1.14M gain in pro forma.
- Pro forma stockholders' equity rises to $82.5M from ($2.1M) deficit at Dec 31, 2023.
- Company believes it now meets Nasdaq's $5M minimum equity requirement for initial listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655124000052/0001516551-24-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655124000052/skye-20240403.htm
  HTML page:      https://secwatch.observer/filing/0001516551-24-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer